DJIA 17,999.46 286.80 1.62%
NASDAQ 4,945.61 54.39 1.11%
S&P 500 2,087.90 26.88 1.30%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

64.41 1.04 (1.64%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ISIS $64.41 1.64%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $64.61
Previous Close $63.37
Daily Range $62.77 - $65.28
52-Week Range $22.25 - $77.80
Market Cap $7.7B
P/E Ratio -192.03
Dividend (Yield) $0.00 (0.0%)
Volume 1,971,798
Average Daily Volume 2,923,912
Current FY EPS -$0.79




Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website:

News & Commentary Rss Feed

Is This The Biggest Threat to Isis Pharmaceuticals Stock?

Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis' drugs might face stiff competition. So are investors being overly optimistic?

iShares Russell 2000 Growth ETF Experiences Big Outflow

ISIS Pharmaceuticals (ISIS) Strong In Pre-Market Trading

ISIS Pharmaceuticals (ISIS) Strong On High Relative Volume Today

May 8th Options Now Available For Isis Pharmaceuticals (ISIS)

Jeff Cooper: Indiscriminate Buying Begets Indiscriminate Selling

Sometimes technical analysis and time cycle work set up in a very compelling manner.

'Mad Money' Lightning Round: Buy, Buy, Buy ConocoPhillips

Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)

Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog

Trade-Ideas: ISIS Pharmaceuticals (ISIS) Is Today's "Dead Cat Bounce" Stock

Jeff Cooper: Biotech and the Dollar Blink

The reversals in biotech and the US dollar are worth watching.

See More ISIS News...

ISIS's Top Competitors

ISIS $64.41 (1.64%)
Current stock: ISIS
AMGN $163.95 (0.84%)
Current stock: AMGN
GILD $100.17 (-0.82%)
Current stock: GILD
BIIB $430.77 (0.21%)
Current stock: BIIB